B1 Marketing Group

B1 Marketing Group B1 Marketing Group is a tech-enabled claimant acquisition firm built for law firms.

Using proprietary software and AI-assistance, we identify and qualify injured individuals for mass tort cases - delivering the right claimants to attorneys, at scale.

Major Development in Spinal Cord Stimulator LitigationThe U.S. Judicial Panel on Multidistrict Litigation (JPML) has cen...
06/10/2026

Major Development in Spinal Cord Stimulator Litigation

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has centralized Boston Scientific spinal cord stimulator lawsuits into a new federal MDL in the Central District of California (MDL No. 3181), assigned to U.S. District Judge Josephine L. Staton.

At least 23 pending cases have been consolidated into the MDL. Plaintiffs allege device failures, lead migration, unintended electrical shocks, burns, battery issues, faulty software, and worsening pain linked to implanted Boston Scientific SCS devices. Boston Scientific opposed the MDL creation.

This consolidation is expected to streamline discovery and pretrial proceedings as the number of claims continues to grow.

Key facts for the litigation:

Only Boston Scientific cases are included; Abbott, Medtronic, and Nevro lawsuits are proceeding individually

The court is in the Central District of California (not Northern District)

No major verdicts or settlements have been reached yet; new lawsuits may still be filed

FDA reports over 80,000 adverse event filings for SCS devices since 2008, including nearly 500 deaths

Recent SCS device generations include multiple waveform options (tonic, burst, microdosing, FAST) that automatically rotate through therapies.

The Suboxone tooth decay litigation continues to move forward in federal court, with approximately 1,833 pending cases i...
06/09/2026

The Suboxone tooth decay litigation continues to move forward in federal court, with approximately 1,833 pending cases in MDL 3092 as of June 2026. The litigation, pending in the U.S. District Court for the Northern District of Ohio before Judge J. Philip Calabrese, centers on allegations that Suboxone film caused serious dental injuries and that adequate warnings were not provided.

Recent court activity shows the litigation remains in the discovery and bellwether preparation phase. Judge Calabrese has continued issuing orders related to the production of medical, dental, and pharmacy records, including show-cause and potential contempt proceedings involving noncompliant entities. No global settlement of the dental injury claims has been publicly announced, and the litigation continues progressing toward bellwether case selection and trial preparation.

For those following the litigation, the key developments are likely to continue involving discovery disputes, scheduling orders, and bellwether preparation rather than any immediate global resolution.

Olympus colonoscopy and endoscopy devices continue to face legal scrutiny as patients report serious infections allegedl...
06/08/2026

Olympus colonoscopy and endoscopy devices continue to face legal scrutiny as patients report serious infections allegedly linked to contaminated reusable scopes.

Recent lawsuits claim that certain Olympus scopes may retain harmful bacteria even after standard cleaning, and allegations suggest design flaws make certain reusable scopes difficult to fully sterilize.

Reported complications include sepsis, bloodstream infections, antibiotic-resistant "superbug" infections, organ damage, prolonged hospitalization, and in some cases, death.

Common symptoms after a colonoscopy that may indicate infection include fever, chills, abdominal pain, nausea, vomiting, fatigue, and signs that develop days or weeks after the procedure.

Recent reports indicate Olympus scope infection lawsuits are increasing in 2026 as more patients come forward.

⚖️ A major development has emerged in the ongoing Roundup litigation. The proposed $7.25 billion settlement has been tra...
06/07/2026

⚖️ A major development has emerged in the ongoing Roundup litigation. The proposed $7.25 billion settlement has been transferred from Missouri state court to the federal Roundup MDL in California before Judge Vince Chhabria.

The settlement had previously received preliminary approval in Missouri, but objectors challenged the process, arguing that the deal was designed to limit the rights of cancer victims while helping manage Monsanto's liability.

The Judicial Panel on Multidistrict Litigation (JPML) agreed that the case shares common issues with the federal Roundup MDL and ordered the transfer.

The key dispute now centers on where the settlement should be reviewed. Monsanto and the settling plaintiffs want the case returned to Missouri state court, while opponents continue to argue that the settlement deserves closer scrutiny in federal court.

Although this transfer creates an additional procedural hurdle, it does not automatically derail the settlement. The ultimate fate of the agreement remains uncertain as legal battles over jurisdiction and fairness continue.

🔍 The Roundup litigation remains one of the largest and most closely watched mass tort cases in the United States.

Thousands of lawsuits across the United States allege that major social media platforms, including Facebook, Instagram, ...
06/06/2026

Thousands of lawsuits across the United States allege that major social media platforms, including Facebook, Instagram, TikTok, Snapchat, and YouTube, were intentionally designed with features that encourage compulsive use, particularly among children and teenagers.

Recent court developments have allowed many of these claims to move forward, while the number of cases in the federal Social Media Addiction MDL continues to grow.

Plaintiffs claim that addictive platform features such as infinite scroll, autoplay, notifications, and algorithm-driven recommendations contributed to serious mental health harms, including anxiety, depression, eating disorders, self-harm, and other psychological injuries. The companies deny wrongdoing and maintain that they have invested heavily in user safety and parental controls.

As litigation progresses, these cases could have a significant impact on how technology companies design products for young users and how responsibility for online harms is addressed in the future. ⚖️

⚠️ EMERGING PHARMACEUTICAL LITIGATION: Gabapentin-Dementia ResearchGabapentin (Neurontin®) is one of the most widely pre...
06/05/2026

⚠️ EMERGING PHARMACEUTICAL LITIGATION: Gabapentin-Dementia Research

Gabapentin (Neurontin®) is one of the most widely prescribed medications in the United States. FDA-approved for treating certain nerve pain and seizures, it's commonly prescribed off-label for back pain and migraines. In 2024, 15.5 million Americans received gabapentin prescriptions, making it the 5th most prescribed drug in the U.S., with prescriptions nearly tripling since 2010.

New Research Findings (BMJ Group, July 2025)
Study published in Regional Anesthesia & Pain Medicine reveals potential cognitive risks:

29% increased risk of dementia for patients with 6+ gabapentin prescriptions

85% increased risk of mild cognitive impairment (MCI) in the same group

Risk increases with frequency: 12+ prescriptions = 40% higher dementia risk, 65% higher MCI risk

Cognitive Impairment Symptoms Include:
→ Memory loss
→ Confusion
→ Early-onset dementia

Litigation Status
Manufacturer: Pfizer (Neurontin®)

Allegations: Pfizer allegedly failed to adequately warn patients and physicians about cognitive decline risks associated with prolonged gabapentin use.

Current Legal Status:

Individual lawsuits filed nationwide (no formal mass tort yet as of 2026)

Potential class action emerging as of January 2026 for patients with neurological/cognitive injuries

Eligibility considerations: Used gabapentin 6+ times (2000-2024), prescribed for off-label conditions, developed cognitive decline/dementia

Sources: BMJ Group, PubMed, CDC, Annals of Internal Medicine, Simmons Firm, Sokolove Law

Mass tort firms aren’t struggling with lead volume.They’re struggling with lead quality. Our AI-powered claimant verific...
06/04/2026

Mass tort firms aren’t struggling with lead volume.
They’re struggling with lead quality.

Our AI-powered claimant verification platform helps firms identify qualified cases faster through real-time screening, fraud detection, duplication checks, and intelligent intake workflows.

Built for Talcum Powder, Ozempic, Depo-Provera, Roblox, and emerging mass tort litigation.

The future of claimant acquisition isn’t more volume.
It’s smarter validation.

✔ AI-driven intake verification
✔ Real-time fraud & duplicate detection
✔ Faster claimant qualification
✔ Built for modern mass tort litigation

See how technology is changing mass tort acquisition.
Message us for a live demo.

Once marketed for its convenience, one shot every three months, Depo-Provera is now at the heart of one of 2026's defini...
06/03/2026

Once marketed for its convenience, one shot every three months, Depo-Provera is now at the heart of one of 2026's defining mass tort battles. Pfizer faces growing claims from women who say long-term use caused meningioma, a rare brain tumor.

For years, Pfizer argued it couldn't strengthen warnings without FDA approval. That defense cracked in December 2025, when the FDA finally required a meningioma warning on the U.S. label, something plaintiffs had pushed for years.

Since then, the floodgates have opened. The MDL (No. 3140) before Judge M. Casey Rodgers in the Northern District of Florida has surged past 3,700 federal cases as of June 2026, with state filings pushing the total above 4,000, including a 47.7% jump in just one month between February and March.

A pivotal Daubert hearing on the science is set for June 24–25, 2026, and the first bellwether trial is locked in for December 7, 2026, with a Florida woman's case leading the way. More bellwether trials follow in January 2027.

From a quiet contraceptive shot to a courtroom showdown, Depo-Provera is shaping how pharma mass torts get fought and how soon "we couldn't add a warning" stops being a defense.

CeraVe and parent company L’Oréal are facing at least six class-action lawsuits over allegations that certain benzoyl pe...
06/02/2026

CeraVe and parent company L’Oréal are facing at least six class-action lawsuits over allegations that certain benzoyl peroxide (BPO) acne treatments can degrade into benzene, a known human carcinogen, under common storage and use conditions.

Independent testing by Valisure in March 2024 found that products including CeraVe Acne Foaming Cream Cleanser can form benzene at levels significantly above the FDA’s conditional limit of 2 parts per million (reported ranges of 5–12 ppm or higher in heat-stressed conditions). Similar concerns were raised for products like La Roche-Posay Effaclar Duo.

Plaintiffs, including Hawaii resident Jennifer Snow (whose suit was filed in early 2024), allege that L’Oréal failed to adequately warn consumers about this instability, particularly when products are exposed to elevated temperatures such as body heat, warm bathrooms, or during distribution.

As of early 2025, L’Oréal has opposed consolidation of the cases into multidistrict litigation (MDL), with hearings previously scheduled before the U.S. Judicial Panel on Multidistrict Litigation.

Key takeaway for legal professionals: This litigation highlights ongoing scrutiny of product stability testing, failure-to-warn claims, and consumer exposure risks in over-the-counter skincare and pharmaceuticals. Long-term users of affected BPO products may wish to review storage guidelines, consult healthcare providers, and monitor official FDA updates or recalls (note: FDA testing led to limited voluntary recalls of specific lots from various brands, but no broad CeraVe recall at the time of reporting).

This remains a developing matter worth tracking for mass tort, consumer protection, and product liability practices.

Major Update in Bard PowerPort Litigation: Second Bellwether Trial Set for August 2026The court is moving forward with k...
06/01/2026

Major Update in Bard PowerPort Litigation: Second Bellwether Trial Set for August 2026The court is moving forward with key early trials that could impact thousands of cases nationwide.

U.S. District Judge David G. Campbell has decided not to replace a bellwether case after the plaintiff’s death. The remaining five trials will still serve as a sufficient test of the claims.

The second bellwether trial involving a port catheter fracture claim is now scheduled for August 18, 2026.

More than 3,000 Bard PowerPort lawsuits are consolidated in the MDL. Plaintiffs allege the devices were defectively designed with barium sulfate, causing material degradation, fractures, migrations, infections, blood clots, and other serious injuries. They claim Bard failed to provide adequate warnings despite known risks.

The first bellwether trial delivered a mixed result: a defense verdict on some claims, but the jury could not reach a unanimous decision on design defect.

These bellwether outcomes are critical for driving potential settlements in the mass tort space.

Law firms involved in Bard PowerPort or similar port catheter cases, what are your thoughts on how this will affect resolution strategy?

Address

2162 E Williams Field Road, Ste 111-B 1
Gilbert, AZ
85295

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+18003721442

Website

Alerts

Be the first to know and let us send you an email when B1 Marketing Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share